MRNA · News · 20260804N
Revenue Performance and Mix
Moderna, Inc. · 2026-08-04 · Importance 74 · Surprise 32 · In source text
Moderna reported second-quarter 2026 revenue of $145 million, exceeding analysts’ estimates. The company posted a GAAP loss of $1.97 per share for the quarter. Management reiterated a 2026 revenue-growth target of up to 10%, indicating an expected recovery from pandemic-era COVID vaccine revenue declines through newer products and pipeline programs.
Key facts
- Moderna reported revenues of $145 million for the quarter and a GAAP loss of $1.97 per share. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | realized | — | Moderna reported revenues of $145 million for the quarter and a GAAP loss of $1.97 per share. |
| net_income | negative | realized | — | Moderna reported revenues of $145 million for the quarter and a GAAP loss of $1.97 per share. |